Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rsv-604. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 16/20 | 0.58 |
| ▸ | CCKAR | P32238 | 9/20 | 0.55 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rsv-604 SCHEMBL2203787 | 1.00 | CCKBR (0.58) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL1016243 | 0.99 | CCKBR (0.59) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL1016244 | 0.99 | CCKBR (0.59) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL31143725 | 0.92 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL641779 | 0.92 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL641780 | 0.92 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL29670099 | 0.92 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL29351170 | 0.92 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| SCHEMBL644302 | 0.82 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| SCHEMBL642491 | 0.80 | CCKBR (0.74) | CCKBRCCKARBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094308-B1 | STABLE PARENTERAL FORMULATION CONTAINING A RSV INHIBITOR OF A BENZODIAZEPINE STRUCTURE | NOVARTIS AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100056500-A1 | Stable Parenteral Formulation | BURANACHOKAISAN THITIWAN | 2010-03-04 | — | — | US | disclosed |
| EP-2094308-A1 | STABLE PARENTERAL FORMULATION CONTAINING A RSV INHIBITOR OF A BENZODIAZEPINE STRUCTURE | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008063634-A1 | STABLE PARENTERAL FORMULATION CONTAINING A RSV INHIBITOR OF A BENZODIAZEPINE STRUCTURE | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056500-A1 | Stable Parenteral Formulation | GABRA5, GABRA6, GABRP | CCKBR 1286/4885CCKAR 1548/4885BDKRB1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.